(Q37913996)

25 August 2017

1 reference

title

Radioiodine for remnant ablation and therapy of metastatic disease (English)

1 reference

25 August 2017

Christoph Reiners

1

1 reference

25 August 2017

Heribert Hänscheid

2

1 reference

25 August 2017

Markus Luster

3

1 reference

25 August 2017

Michael Lassmann

4

1 reference

25 August 2017

Frederik A Verburg

5

1 reference

25 August 2017

publication date

9 August 2011

1 reference

Nature Reviews Endocrinology

25 August 2017

published in

1 reference

25 August 2017

volume

7

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

589-595

1 reference

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Guidelines for radioiodine therapy of differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Papillary and follicular thyroid cancer: impact of treatment in 1578 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Dosimetry and thyroid cancer: the individual dosage of radioiodine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Low versus high I-131 dose for remnant ablation in differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Development and in vitro characterization of human recombinant thyrotropin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

131I effective half-life and dosimetry in thyroid cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Medical management of thyroid cancer: a risk adapted approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Basis for Physician Recommendations for Adjuvant Radioiodine Therapy in Early-Stage Thyroid Carcinoma: Principal Findings of the Canadian-American Thyroid Cancer Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Papillary and follicular thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Long-term results and prognostic factors in patients with differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Follow-up of patients with thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Low iodine diet in I-131 ablation of thyroid remnants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Two weeks of a low-iodine diet are equivalent to 3 weeks for lowering urinary iodine and increasing thyroid radioactive iodine uptake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.134

Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal

31 March 2020

1 reference

12 December 2020

Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma

1 reference

12 December 2020

Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma

1 reference

12 December 2020

Morbidity and mortality in follicular thyroid cancer

1 reference

12 December 2020

Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.

1 reference

12 December 2020

Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma.

1 reference

12 December 2020

"High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma

1 reference

12 December 2020

Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach

1 reference

12 December 2020

Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.

1 reference

12 December 2020

Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer

1 reference

12 December 2020

Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients

1 reference

12 December 2020

Thyroid cancer in infants and adolescents after Chernobyl.

1 reference

12 December 2020

Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software

1 reference

12 December 2020

The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer

1 reference

12 December 2020

A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer

1 reference

12 December 2020

Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma

1 reference

12 December 2020

Individualized dosimetry in the management of metastatic differentiated thyroid cancer

1 reference

12 December 2020

Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2011.134

1 reference

Dimensions Publication ID

25 August 2017

1028254145

0 references

1 reference